Patient characteristics at the baseline visits. There were no significant differences between the intervention and control at baseline
| Characteristics | Intervention group (n=170) | Control group (n=147) |
|---|---|---|
| Male (%)/female (%) | 51.8%/48.2% | 55.2%/44.8% |
| Age (year) | 68.0±11.7 | 67.6±11.2 |
| Aboriginal or Torres Strait Islander (%) | 0.0% | 0.7% |
| Diagnosis | ||
| Type 2 diabetes | 37.6% | 47.6% |
| CHD | 45.3% | 35.8% |
| Both | 17.1% | 16.6% |
| Body mass index (kg/m2) | 31.4±6.0 (n=170) | 30.8±6.0 (n=103) |
| Systolic blood pressure (mm Hg) | 134.1±19.0 (n=169) | 133.5±19.6 (n=112) |
| Total cholesterol (mmol/l) | 4.21±0.94 (n=165) | 4.41±1.06 (n=110) |
| Triglycerides (mmol/l) | 1.73±0.88 (n=165) | 1.92±1.37 (n=105) |
| LDL (mmol/l) | 2.22±0.74 (n=159) | 2.37±0.88 (n=89) |
| HDL (mmol/l) | 1.23±0.36 (n=159) | 1.18±0.33 (n=97) |
| HbA1c (mmol/l) | 7.00±1.21 (n=94) | 7.19±1.42 (n=69) |
| PHQ-9 score | 10.7±4.7 (n=164) | 11.6±5.5 (n=146) |
| PHQ-9 score range at baseline | 5–24 | 5–27 |
CHD, coronary heart disease; HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PHQ-9, nine-item Patient Health Questionnaire.